Table 2

Endpoints during follow-up among stage 1 serological suspects who attended at least one control visit, by site

Adjumani, Uganda

Arua, Uganda

Moyo, Uganda

Yumbe, Uganda

Kiri, s. Sudan

Maridi, s. Sudan

Total




Not included in survival analysis

Dead (%)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

1 (0.1)

0 (0.0)

1 (0.03)

Non-case (CATT reactivity waned) (%)

279 (58.1)

1198 (66.4)

13 (27.7)

21 (61.8)

326 (46.6)

51 (45.1)

1888 (59.4)

Persistent suspect (%)

102 (21.3)

491 (27.2)

10 (21.3)

11 (32.4)

330 (47.2)

47 (41.6)

991 (31.2)




Included in survival analysis

Confirmed stage 1 HAT (%)

61 (12.7)

87 (4.8)

18 (38.3)

1 (2.9)

23 (3.3)

9 (8.0)

199 (6.3)

Progressed to stage 2 HAT (%)

38 (7.9)

29 (1.6)

6 (12.8)

1 (2.9)

19 (2.7)

6 (5.3)

99 (3.1)




Total

480

1805

47

34

699

113

3178




Median number of days between detection as stage 1 serological suspect and stage 2 diagnosis (IQR)

179 (99–319)

206 (181–409)

213 (103–417)

198 (single observation)

135 (109–221)

64 (28–168)

189 (104–319)


Checchi et al. BMC Infectious Diseases 2008 8:16   doi:10.1186/1471-2334-8-16

Open Data